X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (45) 45
index medicus (24) 24
colorectal cancer (22) 22
colorectal neoplasms - drug therapy (17) 17
humans (17) 17
cancer (15) 15
care and treatment (14) 14
colorectal neoplasms - pathology (14) 14
metastasis (14) 14
metastatic colorectal cancer (14) 14
aged (12) 12
chemotherapy (12) 12
male (12) 12
bevacizumab (11) 11
female (11) 11
cetuximab (10) 10
colorectal neoplasms - genetics (10) 10
middle aged (10) 10
research (10) 10
colorectal neoplasms - mortality (9) 9
metastases (9) 9
analysis (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
kras (8) 8
neoplasm metastasis (8) 8
camptothecin - analogs & derivatives (7) 7
colorectal carcinoma (7) 7
disease-free survival (7) 7
prognosis (7) 7
aged, 80 and over (6) 6
braf (6) 6
fluorouracil (6) 6
irinotecan (6) 6
mutation (6) 6
open-label (6) 6
patients (6) 6
proto-oncogene proteins b-raf - genetics (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
1st-line treatment (5) 5
adult (5) 5
angiogenesis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
camptothecin - administration & dosage (5) 5
digestive system diseases (5) 5
genetic aspects (5) 5
leucovorin (5) 5
monoclonal antibodies (5) 5
panitumumab (5) 5
ras mutations (5) 5
ras proteins - genetics (5) 5
survival (5) 5
treatment outcome (5) 5
tumors (5) 5
usage (5) 5
anti-egfr monoclonal antibodies (4) 4
bevacizumab - therapeutic use (4) 4
cancer therapies (4) 4
clinical trials (4) 4
kaplan-meier estimate (4) 4
oxaliplatin (4) 4
progression-free survival (4) 4
proportional hazards models (4) 4
proto-oncogene proteins - genetics (4) 4
proto-oncogene proteins p21 (4) 4
therapy (4) 4
trial (4) 4
5-fluorouracil (3) 3
acquired-resistance (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
biochemistry & molecular biology (3) 3
biomarkers (3) 3
cancer patients (3) 3
cell biology (3) 3
colon-cancer (3) 3
colorectal neoplasms - blood (3) 3
combination (3) 3
deoxyribonucleic acid--dna (3) 3
diagnosis (3) 3
dna (3) 3
dna mutational analysis (3) 3
drug therapy (3) 3
epidermal growth factor (3) 3
expression (3) 3
fluorouracil - administration & dosage (3) 3
folfoxiri plus bevacizumab (3) 3
health aspects (3) 3
hematology, oncology and palliative medicine (3) 3
leucovorin - administration & dosage (3) 3
medicine & public health (3) 3
neoplasms (3) 3
non-inferiority (3) 3
oncology, experimental (3) 3
patient outcomes (3) 3
phase-3 trial (3) 3
prospective studies (3) 3
regorafenib (3) 3
resistance (3) 3
retrospective studies (3) 3
settore med/06 - oncologia medica (3) 3
survival analysis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 83 - 90
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in... 
metastatic colorectal cancer | NRAS | BRAF | KRAS | anti‐EGFR | anti-EGFR | 1ST-LINE TREATMENT | N-RAS | MICROSATELLITE INSTABILITY | KRAS WILD-TYPE | COLON-CANCER | PANITUMUMAB | K-RAS | ONCOLOGY | BRAF MUTATIONS | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Liver Neoplasms - mortality | DNA Mutational Analysis | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Liver Neoplasms - secondary | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Liver Neoplasms - genetics | Membrane Proteins - genetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Chemotherapy | Gene mutations | Analysis | Colorectal cancer | Monoclonal antibodies | Genetic aspects | Metastasis | Cancer | Mutation | Medical prognosis | Tumors | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 07/2017, Volume 117, Issue 3, pp. 315 - 321
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, pp. e66774 - e66774
Purpose: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been... 
BIOMARKERS | LEUCOVORIN | CLINICAL-TRIAL DESIGNS | POLYMORPHISMS | MULTIDISCIPLINARY SCIENCES | PHASE-3 TRIAL | RESISTANCE | OXALIPLATIN | FLUOROURACIL | GENETIC-VARIATIONS | CHINESE POPULATION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Neovascularization, Pathologic | Male | Vascular Endothelial Growth Factor A - genetics | Bevacizumab | Vascular Endothelial Growth Factor Receptor-2 - genetics | Neoplasm Metastasis | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Adenocarcinoma - genetics | Retrospective Studies | Drug Therapy, Combination | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Gene Expression | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - blood supply | Treatment Outcome | Adenocarcinoma - drug therapy | Sequence Analysis, DNA | Adenocarcinoma - blood supply | Survival Analysis | Aged | Polymorphism, Single Nucleotide | Adenocarcinoma - mortality | Care and treatment | Vascular endothelial growth factor | Analysis | Risk factors | Colorectal cancer | Impact prediction | Colorectal carcinoma | Clinical trials | Oncology | Single-nucleotide polymorphism | Metastasis | Cancer therapies | Patients | Metastases | Vascular endothelial growth factor receptors | Angiogenesis | Experimental design | Peripheral blood | Biomarkers | Population | Mathematical models | Deoxyribonucleic acid--DNA | Cancer | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2018, Volume 36, Issue 4, pp. 709 - 714
Journal Article
The Oncologist, ISSN 1083-7159, 11/2015, Volume 20, Issue 11, pp. 1261 - 1265
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2018, Volume 13, Issue 3, pp. e0193640 - e0193640
Journal Article